Amgen (AMGN) Invested Capital (2009 - 2026)

Amgen (AMGN) has reported Invested Capital for 18 consecutive years, with $66.5 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Invested Capital rose 4.6% year-over-year to $66.5 billion; the TTM figure through Mar 2026 stood at $66.5 billion (up 4.6% YoY), while the FY2025 annual figure was $63.3 billion, down 4.11% from the prior year.
• Invested Capital came in at $66.5 billion for Q1 2026 at Amgen, up from $63.3 billion in the prior quarter.
• The five-year high for Invested Capital was $70.8 billion in Q4 2023, with the low at $37.8 billion in Q1 2022.
• Average Invested Capital over 5 years is $60.5 billion, with a median of $66.0 billion recorded in 2024.
• Across the five-year window, Invested Capital slipped 10.03% in 2022 and soared 77.04% in 2023, its largest moves.
• Year by year, Invested Capital stood at $42.6 billion in 2022, then jumped by 66.46% to $70.8 billion in 2023, then declined by 6.87% to $66.0 billion in 2024, then declined by 4.11% to $63.3 billion in 2025, then climbed by 5.14% to $66.5 billion in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered $66.5 billion, $63.3 billion, and $64.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.